Drug developers are using surrogate endpoints to monitor the effectiveness of immunotherapies, taking into account the differences between immunotherapy and traditional treatments.
Chris Smyth, PhD
Advertisement
Articles by Chris Smyth, PhD
Gene-editing technology has the ability to give oncology researchers an effective treatment option in the fight against cancer. CRISPR-Cas9 is such a technology that is currently being used to study genes in cancer cells.
Applied Clinical Trials
The smaller biopharmaceutical company perspective on mastering oncology immunotherapy clinical trials.
Advertisement
Latest Updated Articles
Imagining the Impossible: Immunity to CancerApril 1st 2016
- Harnessing CRISPR-Cas9 within Oncology Clinical Research
September 29th 2016
- Developing New Clinical Endpoints for Immuno-Oncology Studies
February 23rd 2017
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?
2
Where AI Leads in Trial Design—and Where Humans Still Need To
3
The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility
4
ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval
5